Pulmonary surfactant, a complex mixture of lipids and proteins, is fundamental to reducing surface tension in the alveoli and maintaining pulmonary stability. Surfactant replacement therapy has revolutionized neonatal care for infants born prematurely with respiratory distress syndrome (RDS). However, variations in treatment efficacy have been observed in infants exhibiting additional pulmonary comorbidities such as bronchopulmonary dysplasia (BPD), persistent pulmonary hypertension of the newborn (PPHN), and congenital pulmonary malformations. This study meticulously stratifies these comorbidities to assess their precise impact on surfactant responsiveness in late preterm babies.

Utilizing data collected from multiple neonatal intensive care units (NICUs) across Europe, the researchers conducted an extensive cohort study involving hundreds of late preterm infants receiving surfactant therapy. Sophisticated statistical models were employed to isolate the effects of specific pulmonary comorbidities from confounding variables, such as gestational age variations, birth weight, and antenatal steroid exposure. The results elucidate that certain comorbidities markedly diminish the effectiveness of standard surfactant formulations, suggesting the need for modified therapeutic strategies.

One of the pivotal discoveries in this study is the differential response related to the presence of inflammatory lung diseases. Infants with underlying pulmonary inflammation showed a significantly blunted improvement in oxygenation indices following surfactant administration compared to their counterparts without inflammation. This finding underscores the crucial interplay between inflammatory processes and surfactant function, providing a potential mechanistic explanation involving surfactant protein degradation and impaired biophysical activity within inflamed alveoli.

Furthermore, the study highlights that late preterm infants with pulmonary hypertension experience altered pulmonary vascular reactivity that interferes with the distribution and efficacy of surfactant delivered via conventional routes. These infants demonstrated protracted ventilatory support requirements and a higher incidence of supplemental oxygen dependency beyond the neonatal period. This observation compels the neonatal community to reconsider current administration protocols, possibly incorporating adjunctive pharmacological agents aimed at modulating vascular tone to optimize surfactant distribution.

Strikingly, the presence of congenital pulmonary malformations such as congenital pulmonary airway malformation (CPAM) or bronchogenic cysts created complex scenarios where surfactant therapy alone failed to reverse respiratory dysfunction effectively. The anatomical aberrations disrupted normal alveolar architecture and surfactant compartmentalization, indicating that surgical correction may be necessary before surfactant therapy can yield optimal results. This revelation calls for a more integrated approach that combines imaging diagnostics, surgical evaluation, and respiratory support strategies in late preterm infants.

The implications of these findings extend beyond immediate treatment protocols. They signify that neonatal intensive care providers must adopt a more nuanced, individualized approach to surfactant replacement therapy, recognizing the heterogeneity within the late preterm population. Precision medicine approaches, integrating patient-specific pulmonary pathology profiles, may enhance survival rates and long-term respiratory outcomes in this fragile demographic. Tailoring surfactant type, dose, and administration technique based on comorbidity profiles may become standard practice in the near future.

Moreover, the study delves into the biochemical alterations in surfactant composition and function associated with different pulmonary comorbidities. Advanced analytical techniques, including mass spectrometry and immunoassays, revealed that surfactant extracted from infants with complicated pulmonary disease exhibits altered lipid-protein ratios and dysfunctional surfactant proteins critical for stability and spreadability. Such molecular insights provide tangible targets for designing next-generation synthetic surfactants or adjunct treatments that replenish deficient components or protect surfactant from inflammatory degradation.

In addition to the biochemical dimension, the research team used high-resolution imaging and lung function measurements to correlate structural abnormalities with functional responses to surfactant therapy. This comprehensive phenotyping approach allowed for the identification of phenotypic biomarkers predictive of poor therapeutic outcomes, enabling early risk stratification and intervention customization. The integration of imaging biomarkers with biochemical data marks a transformative leap in neonatal respiratory research, pointing toward multimodal diagnostics as a cornerstone of future surfactant therapy optimization.

Equally noteworthy is the study’s impact on understanding surfactant pharmacokinetics and biodistribution in the context of pulmonary comorbidities. The researchers used radiolabeled surfactant preparations to track lung deposition in various pathological conditions, revealing that abnormal alveolar-capillary barriers and altered pulmonary fluid dynamics profoundly affect surfactant dispersion and clearance. These insights could inform modified delivery methods, including aerosolized surfactant or surfactant combined with therapeutic nanoparticles, to overcome delivery barriers in diseased lungs.

While surfactant therapy had historically been one-size-fits-all, this study elucidates the importance of precision dosing regimens. Infants with specific comorbidities required adjusted dosing intervals or amounts to achieve adequate alveolar surfactant pools. Over- or under-dosing in these contexts risks exacerbating lung injury or insufficient treatment, respectively. The findings advocate for dynamic dosing algorithms that incorporate real-time markers of lung function and surfactant activity, supported by point-of-care diagnostics.

The study also sheds light on long-term respiratory morbidity related to initial surfactant response variations. Infants with suboptimal therapeutic responses exhibited higher incidences of chronic lung disease and impaired pulmonary function well into infancy and early childhood. These correlations emphasize that early pulmonary comorbidities and surfactant therapy outcomes can have profound lifelong consequences, underscoring the urgency of refining neonatal interventions.

Importantly, the researchers call for further clinical trials that incorporate stratification by pulmonary comorbidity profiles. Such trials are essential to validate tailored surfactant formulations or novel adjunct therapies. The study’s multicenter nature ensures wide applicability of results across diverse healthcare settings but also reveals regional variations in comorbidity prevalence and management practices, highlighting the need for global standardized guidelines informed by these new insights.

In conclusion, this landmark study transforms our understanding of surfactant therapy in late preterm infants by illuminating the significant role of pulmonary comorbidities in shaping treatment outcomes. It bridges molecular biology, pharmacology, and clinical care, offering a comprehensive roadmap for the development of precision respiratory medicine in neonatology. As surfactant replacement continues to be a cornerstone of neonatal intensive care, adapting therapies to address complex pulmonary pathologies holds unprecedented potential to improve survival and quality of life for the most vulnerable newborns.

The research represents a clarion call to clinicians, scientists, and industry to innovate surfactant therapies beyond traditional paradigms and embrace a future of personalized neonatal respiratory care. Neonatologists are now better equipped with the knowledge needed to optimize treatments, mitigate long-term complications, and ultimately enhance the trajectory of infants born at the margins of term. This study not only raises essential scientific questions but also ignites hope for tangible clinical breakthroughs in the care of late preterm infants worldwide.

Subject of Research: Pulmonary comorbidities and their impact on surfactant therapy responsiveness in late preterm infants

Article Title: Pulmonary comorbidities and response to surfactant in late preterm infants: a multicenter cohort study

Article References:
Sadowska-Krawczenko, I., Hożejowski, R., Mazela, J. et al. Pulmonary comorbidities and response to surfactant in late preterm infants: a multicenter cohort study. Pediatr Res (2025). https://doi.org/10.1038/s41390-025-04634-5

Image Credits: AI Generated

DOI: 01 December 2025

Congenital diaphragmatic hernia, a developmental defect characterized by incomplete formation of the diaphragm, allows abdominal organs to herniate into the thoracic cavity, compromising lung development and function. Infants born with CDH often face severe respiratory distress due to hypoplastic lungs and pulmonary hypertension. Despite advances in neonatal intensive care, mortality and morbidity remain high, primarily because of inadequate understanding and monitoring of lung function dynamics at the regional level within the compromised lungs. Traditional imaging modalities such as chest X-rays and computed tomography scans lack the resolution and safety profiles necessary for continuous bedside assessment, especially in fragile neonates.

This new investigative approach harnesses electrical impedance tomography — a noninvasive imaging technique that maps the distribution of electrical conductivity across the thorax to infer regional ventilation patterns. By analyzing impedance changes associated with inhaled air volumes, EIT offers a functional map of how different lung regions are ventilated over time without exposing the patient to ionizing radiation. The implications for managing infants with CDH are profound, as EIT could enable clinicians to track lung recruitment and detect ventilation heterogeneity dynamically, adjusting respiratory support strategies in real time.

The research team embarked on a detailed evaluation of regional lung function in a cohort of infants diagnosed with CDH, employing EIT immediately postnatal and during the course of intensive respiratory management. Their findings revealed that ventilation in affected lungs is not uniformly distributed; rather, there exist distinct zones of disproportionate aeration, which fluctuate with evolving clinical interventions. These heterogeneous ventilation patterns reflect the underlying structural abnormalities and mechanical stiffness caused by pulmonary hypoplasia, emphasizing the need for individualized ventilatory settings to minimize volutrauma and atelectasis.

Importantly, the study underscored the limitations of global respiratory parameters conventionally used in clinical practice, such as oxygenation indices and blood gas analysis, which inadequately represent the complex internal mechanics of a CDH-affected lung. Through EIT-derived regional indices, clinicians can visualize real-time ventilation distribution shifts, gaining insights into which lung segments are adequately aerated and which remain compromised. This level of detail allows for titration of positive end-expiratory pressure (PEEP) and other ventilation parameters with a tailored approach aimed at maximizing alveolar recruitment while minimizing ventilator-induced lung injury.

Moreover, this research marks a significant step toward early prognostication in CDH, as variations in regional lung function detected via EIT correlated with clinical outcomes such as duration of mechanical ventilation and survival rates. Early identification of lung regions prone to collapse or overdistension could guide therapeutic decision-making and prompt timely interventions, potentially improving long-term respiratory prognosis and reducing associated comorbidities. The ability to monitor lung function continuously at the bedside presents an invaluable tool for neonatologists attempting to navigate the precarious balance between adequate oxygenation and lung protection.

Technically, EIT in neonatal populations presents its own set of challenges, including the need for appropriately sized electrode arrays and the interpretation of data in a rapidly changing thoracic physiology. The authors innovated by adapting electrode placement specific to the small thoracic circumference of neonates with CDH and refined computational algorithms to enhance imaging resolution and artifact reduction. Their methodological advancements assure the robustness and reliability of EIT data, paving the way for its integration into routine clinical monitoring in neonatal intensive care units worldwide.

The clinical utility of this research extends beyond CDH, offering a model for the assessment of heterogeneous lung diseases in neonates. Conditions such as bronchopulmonary dysplasia and acute respiratory distress syndrome share the fundamental problem of uneven ventilation, which EIT can characterize dynamically. The noninvasive, radiation-free nature of EIT makes it especially attractive for repeated measurements necessary in fragile infants, allowing clinicians to track disease progression and response to therapy with unprecedented fidelity.

Beyond clinical implications, the study also contributes to refining the understanding of neonatal lung biomechanics. Data generated by EIT provide insight into how lung compliance and resistance vary across diseased segments, informing not only bedside strategies but also the development of predictive computational models of lung behavior. Such models could simulate various ventilatory strategies to optimize lung recruitment and reduce injury, ultimately leading to personalized respiratory management protocols informed by real-time functional imaging.

In addition to the direct impact on patient care, the research team highlights the potential integration of EIT data with other physiological monitoring modalities, such as near-infrared spectroscopy and capnography. This multimodal approach could offer a comprehensive view of pulmonary and systemic function, enhancing diagnostic precision and tailoring therapeutic interventions more effectively. The convergence of these technologies epitomizes the future of neonatal intensive care, where detailed physiological insights drive better outcomes.

As neonatal medicine strives toward precision and minimally invasive technologies, this study’s validation of EIT for regional lung function assessment in CDH patients heralds a paradigm shift. The ability to visualize and quantify lung ventilation heterogeneity in real time empowers clinicians to transcend the guesswork and anecdotal experience traditionally associated with ventilator management. This innovation aligns with broader trends toward functional phenotyping and personalized medicine in respiratory care, with important implications for survival and quality of life in this vulnerable population.

Nevertheless, the authors acknowledge that, while promising, EIT technology and its application in neonatal CDH require further refinement and multicentric validation to establish standardized clinical protocols. Future research will need to address long-term impacts of EIT-guided ventilation strategies on respiratory outcomes and neurodevelopment, as well as integrate EIT into decision-support algorithms harnessing artificial intelligence for automated interpretation and intervention recommendations.

This study’s ripple effect is poised to inspire a cascade of research exploring various congenital and acquired neonatal respiratory disorders with EIT, accelerating progress toward noninvasive, continuous, individualized respiratory monitoring. As neonatal intensive care embraces this technology, the ultimate beneficiaries will be the tiniest patients, whose fragile lungs stand to gain the clearest window yet into their function and healing potential.

In sum, the pioneering work by Douglas, Ferguson, and Tingay etches a powerful new chapter in neonatal respiratory care by demonstrating that electrical impedance tomography transcends mere imaging to become a vital functional tool in confronting one of the most formidable challenges—regional lung dysfunction in congenital diaphragmatic hernia. This innovation not only promises to improve survival and reduce morbidity but also exemplifies the transformative potential of integrating sophisticated physiological monitoring into clinical care for the most vulnerable patients.

Subject of Research: Regional lung function assessment in congenital diaphragmatic hernia using electrical impedance tomography.

Article Title: Regional lung function in congenital diaphragmatic hernia assessed using electrical impedance tomography.

Article References:
Douglas, E., Ferguson, K.N. & Tingay, D.G. Regional lung function in congenital diaphragmatic hernia assessed using electrical impedance tomography. Pediatr Res (2025). https://doi.org/10.1038/s41390-025-04185-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41390-025-04185-9